Advisory Board

Chairman: Robert Derham, Founder & President, CheckOrphan
Robert Derham is the founder and President of CheckOrphan (501c3 and registered non-profit in Switzerland), which is best described as the CNN/BBC for rare diseases. In the past, he has success-fully launched interactive and dynamic life-science-based websites for the following companies: Axxora, BioValley, mondoBIOTECH, Novartis, and Syngenta. Robert is also a member and co-founder of the Global Web-Strategy Network, which consists of representatives from international companies such as: Novartis, Credit Suisse, UN, Nestlé and more. Robert blends 12 years of industry experience and 7 years of research experience, which helps to understand the evolving field of rare diseases and healthcare.

Anders Waas, CEO, Tikomed, Sweden
Anders has over two decades of experience in the pharmaceutical, biotech and medical device industries. He is CEO at TikoMed, a company developing products for severe and Orphan diseases. He has been the Director of Karo Bio since July 2011. From 2004 to 2008, he was Vice President Business Development at CV Therapeutics in Palo Alto (US). Between 1992 and 2004 he held various senior management positions in business development, marketing and product development at Astra and AstraZeneca. These included: Director of Cardiovascular Global Licensing activities at AstraZeneca and Director of Strategic Planning and Business Development for cardiovascular, metabolic and gastrointestinal products at Astra.

Marlene E. Haffner, MD, MPH, CEO, Haffner Associates, LLC (former Director of OOPD at US FDA), USA
Marlene E. Haffner, MD, MPH is the CEO of Haffner Associates, LLC a firm dedicated to the strategy, development and policy of drug development with a special emphasis on rare diseases and the products that treatment them. Prior to establishing her own company, in March 2009, she served as Executive Director, Global Regulatory Policy and Intelligence at Amgen, Inc. For 20 years, Dr. Haffner served as Director of the Office of Orphan Products Development (OOPD) of the Food and Drug Administration (FDA). As OOPD Director she was responsible for the leadership and management of the FDA orphan products development program, the first Orphan Products program in the world. For 36 years she served in the United States Public Health Service beginning her career with the Indian Health Service in Gallup, New Mexico. She received her MD from the George Washington University School of Medicine where she then interned in Internal Medicine. She received further training in internal medicine, dermatology and hematology at the Presbyterian Hospital, New York and that the Albert Einstein College of Medicine, New York. She received an MPH from the Johns Hopkins University Bloomberg School of Public Health. During her Public Health career, she rose to the rank of Rear Admiral in the USPHS. Dr. Haffner has received many awards for her work in drug development including The Outstanding Contributions to Pharmaceutical Medicine Award from the American Academy of Pharmaceutical Physicians, and in May 2009, the Woodrow Wilson Award for Outstanding Government Service from the Johns Hopkins University.

Dr. Hoss A Dowlat, Vice President Regulatory Affairs, Global Strategy, PharmaBio Consulting
Dr. Hoss A Dowlat has more than 31 years of drug development experience in the majority of therapeutic areas in the European and North American Pharma industry, 24 years of which have been in Regulatory Affairs of generics, biosimilars, and original drugs or biologics. Until 2010, Hoss was Vice President, Technical, Drug Development and Regulatory Global Strategy Services, at the leading CRO PAREXEL. In PAREXEL CONSULTING 2000-2010 he served 50 client companies from across Europe, America, Canada, Korea, Japan, and India, leading multidisciplinary teams of up to 40. He currently provides drug development, registration and due diligence support, for Pharma industry and Financial institutions with regional and international presence.

jeannordstromJean Nordstrom, CEO, Sixera Pharma
Industrialist and seasoned manager with 40 years of International Management positions in several Industry sectors. Last 25 years in Pharmaceutical and Biotech. Thorough experience from managing companies with substantial context in development and R&D. Have worked with large companies as well as SMEs.Former Executive President of Pharmacía Spain and member of the Corporate Management group, VP Corporate and Business Development at Arexis AB, Swedish Biotech Company. CEO of Labiana Group, Spanish CMO and producer of own products for human and animal health. Accustomed to work with companies with financial owners as well as industrial partners. Mr. Nordstrom has in parallel to his employments as executive also carried out various assignments as advisor in strategy and development issues. Since 10 years special interest in developing Orphan Drugs. Sixera Pharma is now main focus and Jean Nordstrom is also co-founder and shareholder of the company.

Elizabeth Vroom, Founder and President, Duchenne Parent Project Netherlands
Elizabeth Vroom is founder and president of the Duchenne Parent Project Netherlands since 1995. This organisation has played an active role in drug development for Duchenne Muscular Dystophy. Elizabeth is Chair and co-founder of the worldwide organisation UPPMD (United Parent Projects Muscular Dystrophy). She serves on several advisory boards regarding Care, Research, Ethics, Development of new medicines and Regulatory Issues in the Netherlands as well as international. She received the Biofarmind Innovation Award for her “creative and innovative activities in the field of drug development”. As President of the foundation ‘The Meeting’ she works on projects to optimize the role of patient organisations in drug development.